1 Min Read
May 24 (Reuters) -
* Orphomed secures $39 million series A financing round
* Orphomed says capital will be used to advance clinical development of its lead candidate, ORP-101, for treatment of IBS-diarrhea Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.